As the Smirk Turns, FDA’s Opioid Plan, And A Gene Editing IPO

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Vertex’s Next Big Thing, Regeneron’s Cell Therapy Play, & Takeda Bets on Protagonist
Sanofi Shells Out for Inhibrx, CG’s Breakout IPO, & a Cure for a Rare Deafness
GSK Buys TSLP Antibody, J&J’s ADC Play, & Merck Adds Harpoon T-Cell Engagers
Karuna and RayzeBio Acquired, TCGX’s $1B Crossover Bet, & Cytokinetics’ Breakout